Asunto(s)
Infecciones por Virus de Epstein-Barr/complicaciones , Inmunosupresores/efectos adversos , Metotrexato/efectos adversos , Úlceras Bucales/virología , Anciano , Infecciones por Virus de Epstein-Barr/inmunología , Humanos , Huésped Inmunocomprometido , Trastornos Linfoproliferativos/inmunología , Trastornos Linfoproliferativos/patología , Trastornos Linfoproliferativos/virología , Masculino , Úlceras Bucales/inmunología , Úlceras Bucales/patologíaRESUMEN
Chromosome analysis of a patient with intravascular large B-cell lymphoma (IVL) revealed a complex, near-tetraploid karyotype with 83 chromosomes. Abnormalities included a t(11;14)(q13;q32), which was confirmed with both interphase fluorescence in situ hybridization (FISH) using an IGH/cyclin D1 dual-color, dual-fusion probe set and cyclin D1 immunohistochemical analysis. Abnormality of 3q was also evident. Interphase FISH analysis with a dual-color, break-apart probe set confirmed rearrangement of BCL6. To our knowledge, this is the first report of these abnormalities in IVL.
Asunto(s)
Cromosomas Humanos Par 11 , Cromosomas Humanos Par 14 , Proteínas de Unión al ADN/genética , Linfoma de Células B/genética , Linfoma de Células B Grandes Difuso/genética , Poliploidía , Translocación Genética , Neoplasias Vasculares/genética , Femenino , Humanos , Cariotipificación , Linfoma de Células B/patología , Linfoma de Células B Grandes Difuso/patología , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-bcl-6 , Células Tumorales Cultivadas , Neoplasias Vasculares/patologíaAsunto(s)
Cromosomas Humanos Par 14/genética , Cromosomas Humanos Par 9/genética , Linfoma de Células B/genética , Recurrencia Local de Neoplasia/genética , Neoplasias del Bazo/genética , Translocación Genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Femenino , Humanos , Hibridación Fluorescente in Situ , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/patología , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/genética , Linfoma de Células B Grandes Difuso/patología , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Neoplasias del Bazo/tratamiento farmacológico , Neoplasias del Bazo/patologíaRESUMEN
Thalidomide maintenance has unresolved issues regarding dosage and toxicity. We evaluated this in five dose cohorts in 100 patients. At a median follow-up of 32.3 months, 23 patients had stopped thalidomide for disease progression, 54 for side effects. 3-year overall and progression-free survival was 76% and 41% respectively. Dosage did not influence disease outcome but greatly affected toxicity. Fifteen patients converted from partial remission to complete remission on thalidomide at a median of 13.5 months. Maintenance doses >200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time.